Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
Data support that antibiotic aztreonam-avibactam (ATM-AVI) is effective and well-tolerated in treating infections caused by Gram-negative bacteria, with a similar safety profile to aztreonam alone
Aim is to predict novel catalysts using machine learning (ML) and artificial intelligence (AI) techniques
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
_256_384.jpg)
HMD had supplied 921.7 million syringes to the Government of India to facilitate over 2.2 billion Vaccination in India till date
With over 150 leading companies, 300+ topline brands and knowledge-led conference sessions, the event is set to make a grand return to the South
The company reported lifetime high EBIDTA of Rs. 250 crores
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
The company has reported total income of Rs. 1682.45 crores during the period ended March 31, 2023
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Subscribe To Our Newsletter & Stay Updated
